Pairnomix CEO To Highlight Role Of Genetic Modeling In Treatment Selection At Antiepileptic Drug And Device Trials (AEDD) Conference

MAPLE GROVE, Minn., May 16, 2017 /PRNewswire/ -- Pairnomix, LLC, a personalized genetic evaluations company, today announced that CEO Matthew Fox will participate in a debate at the 14^th conference on Antiepileptic Drug and Device Trials (AEDD). Entitled Models of Genetic Syndromes Will Lead to Targeted Therapies, the debate will also feature Dr. Gregory Krauss, MD, Professor of Neurology at the Johns Hopkins University School of Medicine. This event will take place on Wednesday, May 17 at 9:15 am at the Turnberry Isle Miami Hotel.

The AEDD conference brings together representatives from academia, industry, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) to focus on issues related to antiepileptic drug and device development from preclinical discoveries through clinical evaluations. This year's conference is being held from May 17-19 in Aventura, Florida.

About Pairnomix  
Pairnomix™, a personalized genetic evaluations company, is committed to helping people living with rare diseases understand the genetic cause of their condition and explore potential treatment options that are available today. Pairnomix' initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.

SOURCE Pairnomix

Related Links

http://www.pairnomix.com